drugset / Trial / NCT05129033

A Prospective Study on Optimizing Treatment for ABPA

NCT05129033

Unknown 100 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.

Timeline

Start
2021-11-15
Primary completion
2023-06-30
Completion
2023-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Itraconazole Small molecule 100 mg Oral
Comparator Omalizumab Monoclonal antibody 600 mg Subcutaneous
Comparator Prednisone Other / unclassified 0.5 mg/kg Oral